Bank Julius Baer & Co. A.G., Guernsey Branch Stock

Certificat

SBSQJB

CH1324323323

Market Closed - Swiss Exchange 11:20:00 2024-06-14 am EDT
99.65 CHF -0.15% Intraday chart for Bank Julius Baer & Co. A.G., Guernsey Branch
1 month-0.75%
Date Price Change
24-06-14 99.65 -0.15%
24-06-11 99.8 -0.10%

Delayed Quote Swiss Exchange

Last update June 14, 2024 at 11:20 am EDT

More quotes

Static data

Product typeReverse Convertibles
Buy / SellCALL
Underlying BASILEA PHARMACEUTICA AG
Issuer Bank Julius Bär
SBSQJB
ISINCH1324323323
Date issued 2024-03-12
Strike 37.9 CHF
Maturity 2025-06-12 (363 Days)
Parity 0.04 : 1
Emission price 100 CHF
Emission volume N/A
Settlement both
Currency CHF

Technical Indicators

Highest since issue 101 CHF
Lowest since issue 97.5 CHF
Spread 5 CHF
Spread %0.50%

Company Profile

Basilea Pharmaceutica AG Allschwil, formerly known as Basilea Pharmaceutica AG, is a Switzerland-based commercial-stage biopharmaceutical company. The Company operates in one segment, which is the discovery, development, and commercialization of pharmaceutical products to meet the needs of patients with severe bacterial and fungal infections. It launched two hospital brands, Cresemba, which is an intravenous and oral drug for the treatment of invasive fungal infections, and Zevtera, which is an intravenous antibiotic for the treatment of severe bacterial infections, especially pneumonia. Additionally, the Company has several preclinical anti-infective assets in their portfolio. Company's products are present in United States, Canada, Europe, Asia, and Africa.
Sector
-
More about the company

Ratings for Basilea Pharmaceutica AG

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Consensus: Basilea Pharmaceutica AG

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
42.05 CHF
Average target price
70.58 CHF
Spread / Average Target
+67.86%
Consensus
  1. Stock Market
  2. Certificates
  3. SBSQJB Certificat